What is HC Wainwright’s Estimate for KPRX FY2024 Earnings?

Posted by MarketBeat News on Nov 16th, 2024

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX – Free Report) – Analysts at HC Wainwright reduced their FY2024 earnings per share estimates for shares of Kiora Pharmaceuticals in a report released on Monday, November 11th. HC Wainwright analyst Y. Chen now anticipates that the company will earn $1.28 per share for the year, down from their previous estimate of $1.58. HC Wainwright currently has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Kiora Pharmaceuticals’ current full-year earnings is $0.89 per share. HC Wainwright also issued estimates for Kiora Pharmaceuticals’ Q4 2024 earnings at ($0.74) EPS, Q1 2025 earnings at $0.67 EPS and FY2025 earnings at ($2.76) EPS.

Kiora Pharmaceuticals Trading Down 3.1 %

KPRX opened at $3.29 on Thursday. The company’s 50-day moving average price is $3.52 and its 200 day moving average price is $4.27. Kiora Pharmaceuticals has a fifty-two week low of $3.00 and a fifty-two week high of $8.98.

Want More Great Investing Ideas?

Kiora Pharmaceuticals (NASDAQ:KPRX – Get Free Report) last posted its quarterly earnings results on Friday, November 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.09.

Institutional Trading of Kiora Pharmaceuticals

An institutional investor recently bought a new position in Kiora Pharmaceuticals stock. Stonepine Capital Management LLC acquired a new position in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX – Free Report) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 200,000 shares of the company’s stock, valued at approximately $840,000. Kiora Pharmaceuticals comprises 0.8% of Stonepine Capital Management LLC’s holdings, making the stock its 16th biggest position. Stonepine Capital Management LLC owned about 6.86% of Kiora Pharmaceuticals at the end of the most recent quarter. 76.97% of the stock is currently owned by hedge funds and other institutional investors.

Kiora Pharmaceuticals Company Profile

(Get Free Report)

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.